InflaRx's Vilobelimab Suppresses Inflammation In Mid-Stage Chronic Skin Disorder Study

  • InflaRx NV (NASDAQ: IFRX) has announced new data Phase 2b SHINE study, evaluating vilobelimab (IFX-1) in moderate and severe Hurley Stage II and III hidradenitis suppurativa (HS), a chronic skin condition characterized by the formation of painful lumps under the skin typically in the armpit, groin and genitalia regions.
  • Updated data demonstrated dose-dependent suppression of elevated C5a levels. Within the high-dose treatment group (1200 mg q2w), C5a levels were suppressed to levels below normal median C5a levels of healthy humans at day four and week 16 upon initiation of treatment.
  • Vilobelimab is a monoclonal anti-human complement factor C5a antibody and inhibits the complement C5a receptor, which plays a key role in the inflammatory process.
  • Price Action: IFRX stock gained 3.6% at $6.01 in premarket trading on the last check Thursday.

Posted In: Phase 2BBiotechNewsFDAGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.